troglitazone has been researched along with Alloxan Diabetes in 30 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the effect of troglitazone, a new oral antidiabetic agent that potentiates insulin action and reduces insulin resistance, on albuminuria in streptozotocin (STZ)-treated diabetic rats." | 7.69 | Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. ( Fujii, M; Hasegawa, G; Kondo, M; Nakano, K; Shigeta, H; Takemura, R; Yamaguchi, M, 1997) |
| "We studied the effect of troglitazone, a new oral antidiabetic agent that potentiates insulin action and reduces insulin resistance, on albuminuria in streptozotocin (STZ)-treated diabetic rats." | 3.69 | Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. ( Fujii, M; Hasegawa, G; Kondo, M; Nakano, K; Shigeta, H; Takemura, R; Yamaguchi, M, 1997) |
| "Troglitazone (TGZ) treatment, beginning at 6 weeks of age, prevented the hyperglycemia, the hyperlipidemia, and the increase in 11beta-HSD-1." | 1.32 | Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. ( Agarwal, AK; Duplomb, L; Lee, Y; Park, BH; Takaishi, K; Unger, RH; Wang, MY, 2004) |
| "Troglitazone was able to prevent not only diabetic glomerular hyperfiltration and albuminuria, but an increase in mRNA expression of extracellular matrix proteins and transforming growth factor-beta1 in glomeruli of diabetic rats, without changing blood glucose levels." | 1.31 | Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. ( Haneda, M; Isshiki, K; Kikkawa, R; Koya, D; Maeda, S; Sugimoto, T, 2000) |
| "Troglitazone is a novel insulin-sensitizing agent that improves hyperglycemia and hyperinsulinemia in insulin-resistant diabetes mellitus." | 1.31 | Effect of troglitazone on exocrine pancreas in rats with streptozotocin-induced diabetes mellitus. ( Fujiwara, T; Hayashi, N; Horikoshi, H; Shimizu, K; Shiratori, K, 2000) |
| " Finally, 63 was found to normalize glycemia when dosed at 3 mg/kg bid po in the Zucker diabetic fatty rat model of type 2 diabetes." | 1.30 | N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. ( Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ, 1998) |
| "Troglitazone is a new class of antidiabetic agent possessing radical scavenging ability similar to vitamin E." | 1.30 | Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. ( Fujiwara, T; Horikoshi, H; Ikeda, K; Matsuda, K; Ohsawa, T; Okuno, A; Takahashi, S; Ushiyama, S, 1998) |
| "Troglitazone treatment with MLDSTZ injection prevented hyperglycemia (230 +/- 30 mg/dl) and, suppressed insulitis and TNF alpha production from intraperitoneal exudate cells." | 1.30 | Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. ( Fujiwara, T; Fukushige, J; Horikoshi, H; Hosokawa, T; Izumi, T; Kurakata, S; Ogawa, J; Takahashi, S, 1999) |
| "Troglitazone treatment did not attenuate the insulinopenia and hyperglycemia of diabetic rats, but it partially improved the hypertriglyceridemia." | 1.29 | Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. ( Higa, S; Komiya, I; Nagamine, F; Shimabukuro, M; Shinzato, T; Takasu, N, 1996) |
| "Troglitazone was administered orally (0." | 1.29 | Amelioration of hyperglycemia in streptozotocin-induced diabetic rats receiving a marginal mass of islet grafts by troglitazone, an oral antidiabetic agent. ( Ikeda, S; Nagai, T; Nagata, N; Ono, J; Ryu, S; Yasunami, Y, 1996) |
| " Furthermore, 2-deoxyglucose uptake in CS-045-treated adipocytes was increased and the insulin dose-response curve was shifted to the left." | 1.27 | Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. ( Fujiwara, T; Horikoshi, H; Ushiyama, I; Yoshioka, S; Yoshioka, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 15 (50.00) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 3 |
| Blanchard, SG | 3 |
| Brackeen, MF | 1 |
| Brown, KK | 3 |
| Cobb, JE | 3 |
| Collins, JL | 2 |
| Harrington, WW | 2 |
| Hashim, MA | 2 |
| Hull-Ryde, EA | 2 |
| Kaldor, I | 2 |
| Kliewer, SA | 2 |
| Lake, DH | 2 |
| Leesnitzer, LM | 1 |
| Lehmann, JM | 2 |
| Lenhard, JM | 3 |
| Orband-Miller, LA | 1 |
| Miller, JF | 1 |
| Mook, RA | 1 |
| Noble, SA | 2 |
| Oliver, W | 2 |
| Parks, DJ | 3 |
| Plunket, KD | 3 |
| Szewczyk, JR | 1 |
| Willson, TM | 2 |
| Boswell, EG | 1 |
| Charifson, PS | 1 |
| Cooper, JP | 1 |
| Dezube, M | 1 |
| Oplinger, J | 1 |
| Pentti, M | 1 |
| Tong, WQ | 2 |
| Yu, J | 1 |
| Ahn, S | 2 |
| Kim, HJ | 1 |
| Lee, M | 1 |
| Kim, J | 1 |
| Jin, SH | 1 |
| Lee, E | 1 |
| Kim, G | 1 |
| Cheong, JH | 1 |
| Jacobson, KA | 1 |
| Jeong, LS | 1 |
| Noh, M | 1 |
| Arikawa, M | 1 |
| Takahashi, N | 1 |
| Kira, T | 1 |
| Hara, M | 1 |
| Saikawa, T | 1 |
| Sakata, T | 1 |
| Yotsumoto, T | 1 |
| Naitoh, T | 1 |
| Kanaki, T | 1 |
| Matsuda, M | 1 |
| Tsuruzoe, N | 1 |
| Duplomb, L | 1 |
| Lee, Y | 2 |
| Wang, MY | 1 |
| Park, BH | 1 |
| Takaishi, K | 1 |
| Agarwal, AK | 1 |
| Unger, RH | 2 |
| He, Z | 1 |
| Jiang, T | 1 |
| Wang, Z | 1 |
| Levi, M | 1 |
| Li, J | 1 |
| Kannan, Y | 1 |
| Tokunaga, M | 1 |
| Moriyama, M | 1 |
| Kinoshita, H | 1 |
| Nakamura, Y | 1 |
| Li, X | 1 |
| Hansen, PA | 1 |
| Xi, L | 1 |
| Chandraratna, RA | 1 |
| Burant, CF | 1 |
| Meechan, AJ | 1 |
| Henderson, C | 1 |
| Bates, CD | 1 |
| Grant, MH | 1 |
| Tettey, JN | 1 |
| Tominaga, M | 1 |
| Igarashi, M | 1 |
| Daimon, M | 1 |
| Eguchi, H | 1 |
| Matsumoto, M | 1 |
| Sekikawa, A | 1 |
| Yamatani, K | 1 |
| Sasaki, H | 1 |
| Nagai, T | 2 |
| Yasunami, Y | 2 |
| Nagata, N | 2 |
| Ryu, S | 2 |
| Ono, J | 2 |
| Ikeda, S | 2 |
| Shimabukuro, M | 2 |
| Higa, S | 1 |
| Shinzato, T | 1 |
| Nagamine, F | 1 |
| Komiya, I | 1 |
| Takasu, N | 1 |
| Fujii, M | 1 |
| Takemura, R | 1 |
| Yamaguchi, M | 1 |
| Hasegawa, G | 1 |
| Shigeta, H | 1 |
| Nakano, K | 1 |
| Kondo, M | 1 |
| Zhou, YT | 1 |
| Uchiyama, K | 1 |
| Nakai, I | 1 |
| Mitsuo, M | 1 |
| Shimizu, Y | 1 |
| Oka, T | 1 |
| Takata, Y | 1 |
| Kobayashi, M | 1 |
| Qiang, X | 1 |
| Satoh, J | 1 |
| Sagara, M | 1 |
| Fukuzawa, M | 1 |
| Masuda, T | 1 |
| Sakata, Y | 1 |
| Muto, G | 1 |
| Muto, Y | 1 |
| Takahashi, K | 1 |
| Toyota, T | 1 |
| Fujiwara, T | 4 |
| Ohsawa, T | 1 |
| Takahashi, S | 2 |
| Ikeda, K | 1 |
| Okuno, A | 1 |
| Ushiyama, S | 1 |
| Matsuda, K | 1 |
| Horikoshi, H | 5 |
| Shibata, T | 1 |
| Matsui, K | 1 |
| Nagao, K | 1 |
| Shinkai, H | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Mook, R | 1 |
| Novak, PJ | 1 |
| Faison, W | 1 |
| Binz, JG | 1 |
| Oliver, WO | 1 |
| Brown, HR | 1 |
| Menius, JA | 1 |
| Adkison, K | 1 |
| Ogawa, J | 1 |
| Fukushige, J | 1 |
| Hosokawa, T | 1 |
| Izumi, T | 1 |
| Kurakata, S | 1 |
| Isshiki, K | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Maeda, S | 1 |
| Sugimoto, T | 1 |
| Kikkawa, R | 1 |
| Shimizu, K | 1 |
| Shiratori, K | 1 |
| Hayashi, N | 1 |
| Suzuki, A | 1 |
| Yasuno, T | 1 |
| Kojo, H | 1 |
| Hirosumi, J | 1 |
| Mutoh, S | 1 |
| Notsu, Y | 1 |
| Young, ME | 1 |
| Goodwin, GW | 1 |
| Ying, J | 1 |
| Guthrie, P | 1 |
| Wilson, CR | 1 |
| Laws, FA | 1 |
| Taegtmeyer, H | 1 |
| Nicholas, SB | 1 |
| Kawano, Y | 1 |
| Wakino, S | 1 |
| Collins, AR | 1 |
| Hsueh, WA | 1 |
| Yamashita, H | 1 |
| Nagai, Y | 1 |
| Takamura, T | 1 |
| Nohara, E | 1 |
| Kobayashi, K | 1 |
| Yoshioka, T | 2 |
| Aizawa, Y | 1 |
| Fujita, T | 1 |
| Nakamura, K | 1 |
| Sasahara, K | 1 |
| Kuwano, H | 1 |
| Kinoshita, T | 1 |
| Yoshioka, S | 1 |
| Ushiyama, I | 1 |
30 other studies available for troglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experime | 1998 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Topics: Administration, Oral; Animals; Benzoates; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; | 1998 |
Polypharmacology of N
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adiponectin; Animals; | 2017 |
Enhanced inhibition of L-type calcium currents by troglitazone in streptozotocin-induced diabetic rat cardiac ventricular myocytes.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cells, Cultured; Chromans; Diabetes Mel | 2002 |
A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body | 2003 |
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Animals, Genetically Modified; Blotting, Weste | 2004 |
Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription | 2004 |
Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice.
Topics: Animals; Ascitic Fluid; Blood Glucose; Cells, Cultured; Chemotaxis, Leukocyte; Chromans; Cytokines; | 2004 |
Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Down-Regulation; Fatty Acids, Un | 2005 |
Metabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic rats.
Topics: Animals; Cells, Cultured; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; | 2006 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Gluco | 1993 |
A potential solution for the shortage of donors in islet transplantation using a novel oral antidiabetic agent, troglitazone.
Topics: Administration, Oral; Animals; Blood Glucose; Cell Count; Chromans; Combined Modality Therapy; Diabe | 1995 |
Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Experimental; Heart; | 1996 |
Amelioration of hyperglycemia in streptozotocin-induced diabetic rats receiving a marginal mass of islet grafts by troglitazone, an oral antidiabetic agent.
Topics: Animals; Blood Glucose; Chromans; Cytoplasmic Granules; Diabetes Mellitus, Experimental; Endoplasmic | 1996 |
Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Chromans; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Rats; Ra | 1997 |
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Chromans; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin; In | 1998 |
Surgical and chemical approaches to regulate hyperinsulinemia after pancreas transplantation in rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Drainage; Hyperinsulinism; Hypoglycemic Agents; | 1998 |
Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Diabet | 1998 |
Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Chromans; Diabetes Mellitus, Experimental; Dinoprostone; Ep | 1998 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Me | 1999 |
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Topics: Animals; Benzophenones; Chromans; Clone Cells; Diabetes Mellitus, Experimental; Glucose Clamp Techni | 1999 |
Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.
Topics: Animals; Blood Glucose; Chromans; Cricetinae; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 1999 |
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.
Topics: Albuminuria; Animals; Chromans; Diabetes Mellitus, Experimental; Diglycerides; Extracellular Matrix | 2000 |
Effect of troglitazone on exocrine pancreas in rats with streptozotocin-induced diabetes mellitus.
Topics: Animals; Cholecystokinin; Chromans; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Hypogly | 2000 |
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female; | 2000 |
Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids.
Topics: Animals; Aorta; Blood Pressure; Body Weight; Carboxy-Lyases; Chromans; Constriction; Diabetes Mellit | 2001 |
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabet | 2001 |
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
Topics: Albuminuria; Animals; Basement Membrane; Blood Glucose; Blood Pressure; Body Weight; Chromans; Creat | 2002 |
Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045.
Topics: Animals; Biotransformation; Chromans; Diabetes Mellitus, Experimental; Glucuronates; Hypoglycemic Ag | 1991 |
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Topics: Adipose Tissue; Animals; Benzopyrans; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus, Expe | 1988 |